Actualités China Dasheng Biotechnology Company (PK) - CDBT | Actions OTCMarkets

Outils de qualité professionnelle, pour des investisseurs individuels.

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

- Statement of Beneficial Ownership (SC 13D)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ /*/) CHINA...

- Statement of Beneficial Ownership (SC 13D)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ /*/) CHINA...

- Statement of Beneficial Ownership (SC 13D)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ /*/) CHINA...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________ FORM 8-K ___________ CURRENT...

- Notification that Annual Report will be submitted late (NT 10-K)

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE...

China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results

-- 3Q09 Revenue Increases 43% Over Prior Year Third Quarter; Net Income Up Over 200%, Exceeding Company's Internal Projections -- GANSU, China...

- Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR...

- Amended Quarterly Report (10-Q/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ...

- Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ...

China Dasheng Biotechnology Company (CDBT.OB) Pre-Announces Fiscal Year 2009 Second Quarter Earnings

-- Estimated FY Q2 2009 sales of $5.66 million increased 20.2% compared to FY Q2 2008. -- Estimated FY H1 2009 sales of $10.77 million increased...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________ FORM 8-K ___________ ...

- Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________ FORM 8-K ___________ ...

- Amended Annual Report (10-K/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.1 to FORM 10-K [ x ] ANNUAL REPORT UNDER...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

China Dasheng Biotechnology Company (PK) (CDBT)

Outils de qualité professionnelle, pour des investisseurs individuels.

CDBT Actualités

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

- Statement of Beneficial Ownership (SC 13D)

- Statement of Beneficial Ownership (SC 13D)

- Statement of Beneficial Ownership (SC 13D)

- Current report filing (8-K)

- Notification that Annual Report will be submitted late (NT 10-K)

China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results

- Quarterly Report (10-Q)

- Amended Quarterly Report (10-Q/A)

- Quarterly Report (10-Q)

China Dasheng Biotechnology Company (CDBT.OB) Pre-Announces Fiscal Year 2009 Second Quarter Earnings

- Current report filing (8-K)

- Quarterly Report (10-Q)

- Current report filing (8-K)

- Amended Annual Report (10-K/A)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

China Dasheng Biotechnology Company (PK) (CDBT) Actualités

China Dasheng Biotechnology Company (PK) (CDBT)

Outils de qualité professionnelle, pour des investisseurs individuels.

CDBT Actualités

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

- Statement of Beneficial Ownership (SC 13D)

- Statement of Beneficial Ownership (SC 13D)

- Statement of Beneficial Ownership (SC 13D)

- Current report filing (8-K)

- Notification that Annual Report will be submitted late (NT 10-K)

China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results

- Quarterly Report (10-Q)

- Amended Quarterly Report (10-Q/A)

- Quarterly Report (10-Q)

China Dasheng Biotechnology Company (CDBT.OB) Pre-Announces Fiscal Year 2009 Second Quarter Earnings

- Current report filing (8-K)

- Quarterly Report (10-Q)

- Current report filing (8-K)

- Amended Annual Report (10-K/A)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités